Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial

World Journal of Biological Psychiatry

Volumn 17, Issue 3, 2016, Pages 230-238

  Lenze, Eric J ^a   Farber, Nuri B ^a   Kharasch, Evan ^a   Schweiger, Julie ^a   Yingling, Michael ^a   Olney, John ^a   Newcomer, John W ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Affective disorders; Antidepressants; Major depressive disorder; Psychopharmacology

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLONIDINE; KETAMINE; ANTIDEPRESSANT AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DELUSION; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERSALIVATION; HYPOTENSION; INSOMNIA; INVOLUNTARY MOVEMENT; MAJOR DEPRESSION; MALE; NAUSEA; NYSTAGMUS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SEDATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VOMITING; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE BLIND PROCEDURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIDEPRESSIVE AGENTS; CLONIDINE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; LINEAR MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; UNITED STATES;

EID: 84959190094     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2016.1142607     Document Type: Article

References (46)

1. L.Akinfiresoye, Y.Tizabi 2013. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology. 230:291–298.
2. R.M.Berman, A.Cappiello, A.Anand, D.A.Oren, G.R.Heninger, D.S.Charney, J.H.Krystal. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 47:351–354.
3. T.A.Bowdle, A.D.Radant, D.S.Cowley, E.D.Kharasch, R.J.Strassman, P.P.Roy-Byrne 1998. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 88:82–88.
4. N.Diazgranados, L.Ibrahim, N.E.Brutsche, A.Newberg, P.Kronstein, S.Khalife, W.A.Kammerer, Z.Quezado, D.A.Luckenbaugh, G.Salvadore, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 67:793–802.
5. W.C.Drevets, M.L.Furey 2010. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biological Psychiatry. 67:432–438.
6. R.S.Duman, G.K.Aghajanian 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science. 338:68–72.
7. J.M.Dwyer, R.S.Duman 2013. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry. 73:1189–1198.
8. C.M.Emnett, L.N.Eisenman, A.M.Taylor, Y.Izumi, C.F.Zorumski, S.Mennerick 2013. Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol Pharmacol. 84:935–947.
9. N.B.Farber 2003. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci. 1003:119–130.
10. N.B.Farber, J.Foster, N.L.Duhan, J.W.Olney 1995. Alpha 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology. 12:347–349.
11. N.B.Farber, S.H.Kim, K.Dikranian, X.P.Jiang, C.Heinkel 2002. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry. 7:32–43.
12. A.Flemenbaum, R.L.Zimmermann 1973. Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep. 32:783–792.
13. M.L.Furey, W.C.Drevets 2006. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 63:1121–1129.
14. M.E.Goldberg, M.C.Torjman, R.J.Schwartzman, D.E.Mager, I.W.Wainer 2011. Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality. 23:138–143.
15. W.Guy 2000. Clinical global impressions (CGI) scale. In: A.J.Rush, editor. Handbook of Psychiatric Measures. Washington (DC): American Psychiatric Association; pp. 100–102.
16. F.Handa, M.Tanaka, T.Nishikawa, H.Toyooka 2000. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study. J Clin Anesth. 12:19–24.
17. P.Hartvig, J.Valtysson, K.J.Lindner, J.Kristensen, R.Karlsten, L.L.Gustafsson, J.Persson, J.O.Svensson, I.Øye, G.Antoni, et al. 1995. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther. 58:165–173.
18. V.Jevtovic-Todorovic, D.F.Wozniak, S.Powell, A.Nardi, J.W.Olney 1998. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res. 781:202–211.
19. R.Lai, N.Katalinic, P.Glue, A.A.Somogyi, P.B.Mitchell, J.Leyden, S.Harper, C.K.Loo. 2014. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 15:579–584.
20. A.C.Leon, L.L.Davis, H.C.Kraemer 2011. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 45:626–629.
21. N.Li, B.Lee, R.J.Liu, M.Banasr, J.M.Dwyer, M.Iwata, X.Y.Li, G.Aghajanian, R.S.Duman. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 329:959–964.
22. M.Liebrenz, R.Stohler, A.Borgeat 2009. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry. 10:640–643.
23. D.A.Luckenbaugh, M.J.Niciu, D.F.Ionescu, N.M.Nolan, E.M.Richards, N.E.Brutsche, S.Guevara, C.A.Zarate. 2014. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 159:56–61.
24. R.Moaddel, S.L.Venkata, M.J.Tanga, J.E.Bupp, C.E.Green, L.Iyer, A.Furimsky, M.E.Goldberg, M.C.Torjman, I.W.Wainer. 2010. A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta. 82:1892–1904.
25. S.A.Montgomery, M.Asberg 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:382–389.
26. C.J.Morgan, A.Mofeez, B.Brandner, L.Bromley, H.V.Curran 2004. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 29:208–218.
27. D.A.Mrazek, J.C.Hornberger, C.A.Altar, I.Degtiar 2014. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 65:977–987.
28. J.W.Murrough, D.V.Iosifescu, L.C.Chang, R.K.Al Jurdi, C.E.Green, A.M.Perez, S.Iqbal, S.Pillemer, A.Foulkes, A.Shah, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 170:1134–1142.
29. M.Naughton, G.Clarke, O.F.O'Leary, J.F.Cryan, T.G.Dinan 2014. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 156:24–35.
30. A.J.Neusy, J.Lowenstein 1989. Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine. J Clin Pharmacol. 29:18–24.
31. J.W.Newcomer, N.B.Farber, V.Jevtovic-Todorovic, G.Selke, A.K.Melson, T.Hershey, S.Craft, J.W.Olney. 1999. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 20:106–118.
32. J.W.Newcomer, N.B.Farber, G.Selke, A.K.Melson, V.Jevtovic-Todorovic, J.W.Olney 1998. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Soc Neurosci Abstr. 24(1):525.
33. M.Niesters, C.Martini, A.Dahan 2014. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 77:357–367.
34. R.Nitta, T.Goyagi, T.Nishikawa 2013. Combination of oral clonidine and intravenous low-dose ketamine reduces the consumption of postoperative patient-controlled analgesia morphine after spine surgery. Acta Anaesthesiol Taiwan. 51:14–17.
35. J.I.NurnbergerJr, M.C.Blehar, C.A.Kaufmann, C.York-Cooler, S.G.Simpson, J.Harkavy-Friedman, J.B.Severe, D.Malaspina, T.Reich. 1994. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 51:849–859. Discussion 863-844.
36. R.Paul, N.Schaaff, F.Padberg, H.J.Moller, T.Frodl 2009. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry. 10:241–244.
37. T.Petersen, G.I.Papakostas, Y.Mahal, W.M.Guyker, E.C.Beaumont, J.E.Alpert, M.Fava, A.A.Nierenberg. 2004. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 19:196–201.
38. T.Petersen, G.I.Papakostas, M.A.Posternak, A.Kant, W.M.Guyker, D.V.Iosifescu, A.S.Yeung, A.A.Nierenberg, M.Fava. 2005. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 25:336–341.
39. K.G.Rasmussen, T.W.Lineberry, C.W.Galardy, S.Kung, M.I.Lapid, B.A.Palmer, M.J.Ritter, K.M.Schak, C.L.Sola, A.J.Hanson, et al. 2013. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol (Oxford). 27:444–450.
40. R.J.Schwartzman, G.M.Alexander, J.R.Grothusen, T.Paylor, E.Reichenberger, M.Perreault 2009. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 147:107–115.
41. M.J.Sigtermans, J.J.van Hilten, M.C.Bauer, M.S.Arbous, J.Marinus, E.Y.Sarton, A.Dahan. 2009. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome Type 1. Pain. 145:304–311.
42. K.Trevino, S.M.McClintock, N.McDonald Fischer, A.Vora, M.M.Husain 2014. Defining treatment-resistant depression: A comprehensive review of the literature. Ann Clin Psychiatry. 26:222–232.
43. L.R.Webster, M.J.Walker 2006. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Am J Ther. 13:300–305.
44. J.B.Williams, K.A.Kobak 2008. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 192:52–58.
45. C.A.ZarateJr, N.Brutsche, G.Laje, D.A.Luckenbaugh, S.L.Venkata, A.Ramamoorthy, R.Moaddel, I.W.Wainer. 2012. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 72:331–338.
46. C.A.ZarateJr, J.B.Singh, P.J.Carlson, N.E.Brutsche, R.Ameli, D.A.Luckenbaugh, D.S.Charney, H.K.Manji. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63:856–864.